



Topamax®
topiramate

NAME OF THE MEDICINAL PRODUCT

Trademark
TOPAMAX®

International Nonproprietary Name
Topiramate

DOSAGE FORMS AND STRENGTHS

Film-coated tablet
Sprinkle capsule

Film-Coated Tablets

The tablets are debossed, engraved or embossed.

25 mg tablet

Round, white tablet imprinted with "TOP" on one side and "25" on the other. Each tablet contains 25 mg of topiramate.

50 mg tablet

Round, light yellow tablet imprinted with "TOP" on one side and "50" on the other. Each tablet contains 50 mg of topiramate.

100 mg tablet

Round, yellow tablet imprinted with "TOP" on one side and "100" on the other. Each tablet contains 100 mg of topiramate.

Sprinkle Capsules

15 mg capsule

Small, white to off-white spheres in a gelatin capsule consisting of a white body with a clear or natural cap, printed in black ink with "TOP" on the cap and "15 mg" on the body. Each capsule contains 15 mg of topiramate.

25 mg capsule

Small, white to off-white spheres in a gelatin capsule consisting of a white body with a clear or natural cap, printed in black ink with "TOP" on the cap and "25 mg" on the body. Each capsule contains 25 mg of topiramate.


For excipients, see *List of Excipients*.

PHARMACOLOGICAL PROPERTIES

Topiramate is designated chemically as 2,3:4,5-bis-*O*-(1-methylethylidene)-β-D-fructopyranose sulfamate.

The empirical formula is C₁₂H₂₁NO₈S. The molecular weight is 339.36.

The structural formula is:



Topiramate is a white crystalline powder having a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethylsulfoxide and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3.

Pharmacodynamic Properties

Pharmacotherapeutic group: other antiepileptics, ATC code: N03AX11.

Topiramate is classified as a sulfamate-substituted monosaccharide. The precise mechanism by which topiramate exerts its antiseizure and migraine prophylaxis effects are unknown. Electrophysiological and biochemical studies on cultured neurons have identified three properties that may contribute to the antiepileptic efficacy of topiramate.

Action potentials elicited repetitively by a sustained depolarization of the neurons were blocked by topiramate in a time-dependent manner, suggestive of a state-dependent sodium channel blocking action. Topiramate increased the frequency at which γ -aminobutyrate (GABA) activated GABA_A receptors, and enhanced the ability of GABA to induce a flux of chloride ions into neurons, suggesting that topiramate potentiates the activity of this inhibitory neurotransmitter.

This effect was not blocked by flumazenil, a benzodiazepine antagonist, nor did topiramate increase the duration of the channel open time, differentiating topiramate from barbiturates that modulate GABA_A receptors.

Because the antiepileptic profile of topiramate differs markedly from that of the benzodiazepines, it may modulate a benzodiazepine-insensitive subtype of GABA_A receptor. Topiramate antagonized the ability of kainate to activate the kainate/AMPA (α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid) subtype of excitatory amino acid (glutamate) receptor, but had no apparent effect on the activity of N-methyl-D-aspartate (NMDA) at the NMDA receptor subtype. These effects of topiramate were concentration-dependent over a range of 1 mM to 200 mM, with minimum activity observed at 1 mM to 10 mM.

In addition, topiramate inhibits some isoenzymes of carbonic anhydrase. This pharmacologic effect is much weaker than that of acetazolamide, a known carbonic anhydrase inhibitor, and is not thought to be a major component of topiramate's antiepileptic activity.

In animal studies, topiramate exhibits anticonvulsant activity in rat and mouse maximal electroshock seizure (MES) tests and is effective in rodent models of epilepsy, which include tonic and absence-like seizures in the spontaneous epileptic rat (SER) and tonic and clonic seizures induced in rats by kindling of the amygdala or by global ischemia. Topiramate is only weakly effective in blocking clonic seizures induced by the GABA_A receptor antagonist, pentylenetetrazole.

Studies in mice receiving concomitant administration of topiramate and carbamazepine or phenobarbital showed synergistic anticonvulsant activity, while combination with phenytoin showed additive anticonvulsant activity. In well-controlled add-on trials, no correlation has been demonstrated between trough plasma concentrations of topiramate and its clinical efficacy. No evidence of tolerance has been demonstrated in man.

Epilepsy clinical trials

The results of controlled clinical trials established the efficacy of TOPAMAX® Tablets and TOPAMAX® Sprinkle Capsules as monotherapy for adults and children (ages 6 and older) with epilepsy, adjunctive therapy in adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary

generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome.

Monotherapy

The effectiveness of topiramate as monotherapy in adults and children 6 years of age and older with newly diagnosed epilepsy was established in 4 randomized, double-blind, parallel-group trials. Study EPMN-106 was conducted in 487 patients (6 to 83 years of age) who had a new diagnosis of epilepsy (partial onset or generalized) or a diagnosis of recurrent epilepsy while not taking antiepileptic drugs (AEDs). Patients were randomized to receive topiramate 50 mg/day or topiramate 400 mg/day. Patients remained in the double-blind phase until they experienced a first partial onset or generalized tonic-clonic seizure, until termination of the double-blind phase 6 months after randomization of the last subject, or until withdrawal for protocol-specified reasons. The primary efficacy assessment was based on the comparison between topiramate dose groups with respect to time to first partial onset or generalized tonic-clonic seizure during the double-blind phase. Comparison of the Kaplan-Meier survival curves of time to first seizure favored topiramate 400 mg/day over topiramate 50 mg/day ($p=0.0002$, log rank test). The separation between the groups in favor of the higher dose group occurred early in the titration phase and was statistically significant as early as 2 weeks post randomization ($p = 0.046$), when, by following the weekly titration schedule, the subjects in the higher dose group had achieved a maximum topiramate dose of 100 mg/day. The higher dose group was also superior to the lower dose group with respect to the proportion of subjects who remained seizure-free, based on the Kaplan-Meier estimates, for a minimum of 6 months of therapy (82.9% vs. 71.4%; $p = 0.005$), and for a minimum of 1 year of therapy (75.7% vs. 58.8%; $p = 0.001$). The ratio of hazard rates for time to first seizure was 0.516 (95% confidence interval, 0.364 to 0.733). The treatment effects with respect to time to first seizure were consistent across various subject subgroups defined by age, sex, geographic region, baseline body weight, baseline seizure type, time since diagnosis, and baseline AED use.

In study YI, a single center study, patients ages 15-63 with refractory partial onset seizures ($n=48$) were converted from their existing treatment to Topamax 100 mg/day or 1000 mg/day as monotherapy. The high dose group was statistically superior to the low dose group for efficacy variables. 54% of high dose patients achieved monotherapy compared with 17% in the low dose group with the difference between the doses being statistically significant ($p=0.005$). The mean time to exit was significantly greater in the high dose group ($p=0.002$). The investigator and subject global evaluations of clinical response statistically favoured the high dose group (≤ 0.002).

In study EPMN-104, adult and pediatric patients (ages 6-85) with recently diagnosed epilepsy ($n=252$) were randomized into the low dose (25 or 50 mg/day) or the high dose group (200 or 500 mg/day) based on their body weight. Overall, 54% of high dose patients and 39% of low dose patients were reported to be seizure free during the double-blind phase ($p=0.022$). The high dose group was also superior to the low dose group with respect to seizure frequency distribution ($p=0.008$) and the difference in time to first seizure across three plasma topiramate concentration strata ($p=0.015$).

In study EPMN-105, patients aged 6-84 with newly diagnosed epilepsy ($n=613$) were randomized to receive either 100 or 200 mg/day of TOPAMAX® or standard anti-epileptic treatment (carbamazepine or valproate). TOPAMAX® was at least as efficacious as carbamazepine or valproate in reducing seizures in these patients; -the 95% confidence intervals for the difference between the two treatment groups were narrow and included zero, indicating that there were no statistically significant between-group difference. The two treatment groups were also comparable with respect to all clinical utility and efficacy endpoints including time to exit, proportion of seizure-free subjects and time to first seizure.

Patients ($n=207$; 32 were aged ≤ 16 years) who completed the double-blind phase of study YI and EPMN-104 were enrolled in long term extension studies with the majority of patients receiving TOPAMAX® for 2 to 5 years. In these studies, sustained efficacy was demonstrated with long-term administration of TOPAMAX® as monotherapy. There was no significant change in dosage during the extension period and no indication that effectiveness of Topamax monotherapy diminished with continued exposure.

Adjunctive therapy

Controlled trials in patients with partial onset seizures

Adults With partial onset seizures

The effectiveness of topiramate as an adjunctive treatment for adults with partial onset seizures was established in six multicenter, randomized, double-blind, placebo-controlled trials, two comparing several

dosages of topiramate and placebo and four comparing a single dosage with placebo, in patients with a history of partial onset seizures, with or without secondarily generalized seizures.

Patients in these studies were permitted a maximum of two AEDs in addition to TOPAMAX® Tablets or placebo. In each study, patients were stabilized on optimum dosages of their concomitant AEDs during baseline phase lasting between 4 and 12 weeks. Patients who experienced a prespecified minimum number of partial onset seizures, with or without secondary generalization, during the baseline phase (12 seizures for 12-week baseline, 8 for 8-week baseline, or 3 for 4-week baseline) were randomly assigned to placebo or a specified dose of TOPAMAX® Tablets in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. In five of the six studies, patients received active drug beginning at 100 mg per day; the dose was then increased by 100 mg or 200 mg/day increments weekly or every other week until the assigned dose was reached, unless intolerance prevented increases. In the sixth study (119), the 25 or 50 mg/day initial doses of topiramate were followed by respective weekly increments of 25 or 50 mg/day until the target dose of 200 mg/day was reached. After titration, patients entered a 4, 8, or 12-week stabilization period. The numbers of patients randomized to each dose, and the actual mean and median doses in the stabilization period are shown in Tables 1 and 2.

Topiramate Dose Summary During the Stabilization Periods of Each of Six Double-Blind, Placebo-Controlled, Add-On Trials in Adults with Partial Onset Seizures^b

| Protocol | Stabilization Dose | Target Topiramate Dosage (mg/day) | | | | | |
|----------|--------------------|-----------------------------------|-----|-----|-----|-----|-------|
| | | Placebo ^a | 200 | 400 | 600 | 800 | 1,000 |
| YD | | 42 | 42 | 40 | 41 | -- | -- |
| | N | 5.9 | 200 | 390 | 556 | -- | -- |
| | Mean Dose | 6.0 | 200 | 400 | 600 | -- | -- |
| | Median Dose | | | | | | |
| YE | | 44 | -- | -- | 40 | 45 | 40 |
| | N | 9.7 | -- | -- | 544 | 739 | 796 |
| | Mean Dose | 10.0 | -- | -- | 600 | 800 | 1,000 |
| | Median Dose | | | | | | |
| Y1 | | 23 | -- | 19 | -- | -- | -- |
| | N | 3.8 | -- | 395 | -- | -- | -- |
| | Mean Dose | 4.0 | -- | 400 | -- | -- | -- |
| | Median Dose | | | | | | |
| Y2 | | 30 | -- | -- | 28 | -- | -- |
| | N | 5.7 | -- | -- | 522 | -- | -- |
| | Mean Dose | 6.0 | -- | -- | 600 | -- | -- |
| | Median Dose | | | | | | |
| Y3 | | 28 | -- | -- | -- | 25 | -- |
| | N | 7.9 | -- | -- | -- | 568 | -- |
| | Mean Dose | 8.0 | -- | -- | -- | 600 | -- |
| | Median Dose | | | | | | |
| 119 | | 90 | 157 | -- | -- | -- | -- |
| | N | 8 | 200 | -- | -- | -- | -- |
| | Mean Dose | 8 | 200 | -- | -- | -- | -- |
| | Median Dose | | | | | | |

^a Placebo dosages are given as the number of tablets. Placebo target dosages were as follows: Protocol Y1, 4 tablets/day; Protocol YD and Y2, 6 tablets/day; Protocol Y3 and 119, 8 tablets/day; Protocol YE, 10 tablets/day.

^b Dose response studies were not conducted for other indications or pediatric partial onset seizures.

Pediatric patients ages 2 - 16 years with partial onset seizures

The effectiveness of topiramate as an adjunctive treatment for pediatric patients ages 2 to 16 years with partial onset seizures was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing topiramate and placebo in patients with a history of partial onset seizures, with or without secondarily generalized seizures.

Patients in this study were permitted a maximum of two AEDs in addition to TOPAMAX® Tablets or placebo. In this study, patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week

baseline phase. Patients who experienced at least six partial onset seizures, with or without secondarily generalized seizures, during the baseline phase were randomly assigned to placebo or TOPAMAX® Tablets in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 25 or 50 mg per day; the dose was then increased by 25 mg to 150 mg/day increments every other week until the assigned dosage of 125, 175, 225, or 400 mg/day based on patients' weight to approximate a dosage of 6 mg/kg per day was reached, unless intolerance prevented increases. After titration, patients entered an 8-week stabilization period.

Controlled trials in patients with primary generalized tonic-clonic seizures

The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-clonic seizures in patients 2 years old and older was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing a single dosage of topiramate and placebo.

Patients in this study were permitted a maximum of two AEDs in addition to TOPAMAX® or placebo. Patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week baseline phase. Patients who experienced at least three primary generalized tonic-clonic seizures during the baseline phase were randomly assigned to placebo or TOPAMAX® in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 50 mg per day for four weeks; the dose was then increased by 50 mg to 150 mg/day increments every other week until the assigned dose of 175, 225, or 400 mg/day based on patients' body weight to approximate a dosage of 6 mg/kg per day was reached, unless intolerance prevented increases. After titration, patients entered a 12-week stabilization period.

Controlled trial in patients with Lennox-Gastaut syndrome

The effectiveness of topiramate as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome was established in a multicenter, randomized, double-blind, placebo-controlled trial comparing a single dosage of topiramate with placebo in patients 2 years of age and older.

Patients in this study were permitted a maximum of two AEDs in addition to TOPAMAX® or placebo. Patients who were experiencing at least 60 seizures per month before study entry were stabilized on optimum dosages of their concomitant AEDs during a four week baseline phase. Following baseline, patients were randomly assigned to placebo or TOPAMAX® in addition to their other AEDs. Active drug was titrated beginning at 1 mg/kg per day for a week; the dose was then increased to 3 mg/kg per day for one week then to 6 mg/kg per day. After titration, patients entered an 8-week stabilization period. The primary measures of effectiveness were the percent reduction in drop attacks and a parental global rating of seizure severity.

In all add-on trials, the reduction in seizure rate from baseline during the entire double-blind phase was measured. The median percent reductions in seizure rates and the responder rates (fraction of patients with at least a 50% reduction) by treatment group for each study are shown below in Table 9. As described above, a global improvement in seizure severity was also assessed in the Lennox-Gastaut trial.

| Table 9: Efficacy Results in Double-Blind, Placebo-Controlled, Add-On Epilepsy Trials | | | | | | | | |
|--|--|---------|-------------------|-------------------|-------------------|-------------------|-----------------|-------------------|
| Target TOPAMAX Dosage (mg per day) | | | | | | | | |
| Study # | # | Placebo | 200 | 400 | 600 | 800 | 1,000 | ≈6mg/kg/day* |
| Partial-Onset Seizures Studies in Adults | | | | | | | | |
| YD | N | 45 | 45 | 45 | 46 | -- | -- | -- |
| | Median % Reduction | 11.6 | 27.2 ^a | 47.5 ^b | 44.7 ^c | -- | -- | -- |
| | % Responders | 18 | 24 | 44 ^d | 46 ^d | -- | -- | -- |
| YE | N | 47 | -- | -- | 48 | 48 | 47 | -- |
| | Median % Reduction | 1.7 | -- | -- | 40.8 ^c | 41 ^c | 36 ^c | -- |
| | % Responders | 9 | -- | -- | 40 ^c | 41 ^c | 36 ^d | -- |
| Y1 | N | 24 | -- | 23 | -- | -- | -- | -- |
| | Median % Reduction | 1.1 | -- | 40.7 ^e | -- | -- | -- | -- |
| | % Responders | 8 | -- | 35 ^d | -- | -- | -- | -- |
| Y2 | N | 30 | -- | -- | 30 | -- | -- | -- |
| | Median % Reduction | -12.2 | -- | -- | 46.4 ^f | -- | -- | -- |
| | % Responders | 10 | -- | -- | 47 ^c | -- | -- | -- |
| Y3 | N | 28 | -- | -- | -- | 28 | -- | -- |
| | Median % Reduction | -20.6 | -- | -- | -- | 24.3 ^c | -- | -- |
| | % Responders | 0 | -- | -- | -- | 43 ^c | -- | -- |
| 119 | N | 91 | 168 | -- | -- | -- | -- | -- |
| | Median % Reduction | 20 | 44.2 ^c | -- | -- | -- | -- | -- |
| | % Responders | 24 | 45 ^c | -- | -- | -- | -- | -- |
| Partial-Onset Seizures Studies in Pediatric Patients | | | | | | | | |
| YP | N | 45 | -- | -- | -- | -- | -- | 41 |
| | Median % Reduction | 10.5 | -- | -- | -- | -- | -- | 33.1 ^d |
| | % Responders | 20 | -- | -- | -- | -- | -- | 39 |
| Primary Generalized Tonic-Clonic^h | | | | | | | | |
| YTC | N | 40 | -- | -- | -- | -- | -- | 39 |
| | Median % Reduction | 9 | -- | -- | -- | -- | -- | 56.7 ^d |
| | % Responders | 20 | -- | -- | -- | -- | -- | 56 ^c |
| Lennox-Gastaut Syndromeⁱ | | | | | | | | |
| YL | N | 49 | -- | -- | -- | -- | -- | 46 |
| | Median % Reduction | -5.1 | -- | -- | -- | -- | -- | 14.8 ^d |
| | % Responders | 14 | -- | -- | -- | -- | -- | 28 ^g |
| | Improvement in Seizure Severity ^j | 28 | -- | -- | -- | -- | -- | 52 ^d |
| <p>Comparisons with placebo: ^ap=0.080; ^bp ≤ 0.010; ^cp ≤ 0.001; ^dp ≤ 0.050; ^ep=0.065; ^fp ≤ 0.005; ^gp=0.071;</p> <p>^h Median % reduction and % responders are reported for PGTC seizures;</p> <p>ⁱ Median % reduction and % responders for drop attacks, i.e., tonic or atonic seizures;</p> <p>^j Percentage of subjects who were minimally, much, or very much improved from baseline.</p> <p>*For Studies YP and YTC, specified target dosages (<9.3 mg/kg/day) were assigned based on subject's weight to approximate a dosage of 6 mg/kg per day; these dosages corresponded to mg/day dosages of 125, 175, 225, and 400 mg/day</p> | | | | | | | | |

Subset analyses of the antiepileptic efficacy of Topamax Tablets in these studies showed no differences as a function of gender, race, age, baseline seizure rate, or concomitant AED.

Migraine clinical trials

The clinical development program to evaluate the efficacy of TOPAMAX® in prophylaxis of migraine included two multicenter, randomized, double-blind placebo-controlled, parallel group pivotal trials conducted in North America (MIGR-001 and MIGR-002). The primary efficacy endpoint was the reduction in migraine headache frequency, as measured by the change in 4-week migraine rate from the baseline

phase to the double-blind treatment phase in each TOPAMAX® treatment group compared to placebo in the intent to treat (ITT) population.

In the first study a total of 469 patients (416 females, 53 males), ranging in age from 13 to 70 years, were randomized and provided efficacy data. Two hundred sixty five patients completed the entire 26-week double-blind phase. The median average daily dosage were 47.8 mg/day, 88.3 mg/day, and 132.1 mg/day in the target dose groups of TOPAMAX® 50, 100, and 200 mg/day, respectively.

The mean migraine headache frequency rate at baseline was approximately 5.5 migraine headaches/28 days and was similar across treatment groups. The change in the mean 4-week migraine headache frequency from baseline to the double-blind phase was -1.3, -2.1 and -2.2 in the TOPAMAX® 50, 100, and 200 mg/day groups, respectively, versus -0.8 in the placebo group. The differences between the TOPAMAX® 100 and 200 mg/day groups versus placebo were statistically significant ($p < 0.001$ for both comparisons).

In the second study a total of 468 patients (406 females, 62 males), ranging in age from 12 to 65 years, were randomized and provided efficacy data. Two hundred fifty five patients completed the entire 26-week double-blind phase. The median average daily dosages were 46.5 mg/day, 85.6 mg/day, and 150.2 mg/day in the target dose groups of TOPAMAX® 50, 100, and 200 mg/day, respectively.

The mean migraine headache frequency rate at baseline was approximately 5.5 migraine headaches/28 days and was similar across treatment groups. The change in the mean 4-week migraine headache period frequency from baseline to the doubleblind phase was -1.4, -2.1, and -2.4 in TOPAMAX® 50, 100, and 200 mg/day groups, respectively, versus -1.1 in the placebo group (see figure 2). The differences between the TOPAMAX® 100 and 200 mg/day groups versus placebo were statistically significant ($p = 0.008$ and < 0.001 , respectively).

In both studies, there were no apparent differences in treatment effect within age, or gender, subgroups. Because most patients were Caucasian, there were insufficient numbers of patients from different races to make a meaningful comparison of race.

An additional supportive study, MIGR-003, demonstrated that TOPAMAX® 100mg/day was comparable in terms of efficacy to propranolol 160 mg/day. There was no statistically significant difference between the two groups in the primary efficacy endpoint.

Pharmacokinetic Properties

The tablet and sprinkle formulations are bioequivalent.

The pharmacokinetic profile of topiramate compared to other AEDs shows a long plasma half-life, linear pharmacokinetics, predominantly renal clearance, absence of significant protein binding, and lack of clinically relevant active metabolites.

Topiramate is not a potent inducer of drug metabolizing enzymes, can be administered without regard to meals, and routine monitoring of plasma topiramate concentrations is not necessary. In clinical studies, there was no consistent relationship between plasma concentrations and efficacy or adverse events.

Absorption

Topiramate is rapidly and well absorbed. Following oral administration of 100 mg topiramate to healthy subjects, a mean peak plasma concentration (C_{max}) of 1.5 mcg/mL was achieved within 2 to 3 hours (T_{max}). Based on the recovery of radioactivity from the urine the mean extent of absorption of a 100 mg oral dose of ^{14}C -topiramate was at least 81%. There was no clinically significant effect of food on the bioavailability of topiramate.

Distribution

Generally, 13 to 17% of topiramate is bound to plasma protein. A low capacity binding site for topiramate in/on erythrocytes that is saturable above plasma concentrations of 4 mcg/mL has been observed. The volume of distribution varied inversely with the dose. The mean apparent volume of distribution was 0.80 to 0.55 L/kg for a single dose range of 100 to 1200 mg. An effect of gender on the volume of distribution

was detected, with values for females circa 50% of those for males. This was attributed to the higher percent body fat in female patients and is of no clinical consequence.

Metabolism

Topiramate is not extensively metabolized (~20%) in healthy volunteers. It is metabolized up to 50% in patients receiving concomitant antiepileptic therapy with known inducers of drug metabolizing enzymes. Six metabolites, formed through hydroxylation, hydrolysis and glucuronidation, have been isolated, characterized and identified from plasma, urine and feces of humans. Each metabolite represents less than 3% of the total radioactivity excreted following administration of ^{14}C -topiramate. Two metabolites, which retained most of the structure of topiramate, were tested and found to have little or no anticonvulsant activity.

Elimination

In humans, the major route of elimination of unchanged topiramate and its metabolites is via the kidney (at least 81% of the dose). Approximately 66% of a dose of ^{14}C -topiramate was excreted unchanged in the urine within four days. Following twice a day dosing with 50 mg and 100 mg of topiramate the mean renal clearance was approximately 18 mL/min and 17 mL/min, respectively. There is evidence of renal tubular reabsorption of topiramate. This is supported by studies in rats where topiramate was co-administered with probenecid, and a significant increase in renal clearance of topiramate was observed. Overall, plasma clearance is approximately 20 to 30 mL/min in humans following oral administration.

Topiramate exhibits low intersubject variability in plasma concentrations and, therefore, has predictable pharmacokinetics. The pharmacokinetics of topiramate are linear with plasma clearance remaining constant and area under the plasma concentration curve increasing in a dose-proportional manner over a 100 to 400 mg single oral dose range in healthy subjects. Patients with normal renal function may take 4 to 8 days to reach steady-state plasma concentrations. The mean C_{max} following multiple, twice a day oral doses of 100 mg to healthy subjects was 6.76 mcg/mL. Following administration of multiple doses of 50 mg and 100 mg of topiramate twice a day, the mean plasma elimination half-life was approximately 21 hours.

Use with other AEDs

Concomitant multiple-dose administration of topiramate, 100 to 400 mg twice a day, with phenytoin or carbamazepine shows dose proportional increases in plasma concentrations of topiramate.

Special populations

Pediatric (up to 12 years of age)

The pharmacokinetics of topiramate in children, as in adults receiving add-on therapy, are linear, with clearance independent of dose and steady-state plasma concentrations increasing in proportion to dose. Children, however, have a higher clearance and a shorter elimination half-life. Consequently, the plasma concentrations of topiramate for the same mg/kg dose may be lower in children compared to adults. As in adults, hepatic enzyme inducing AEDs decrease the steady-state plasma concentrations.

Elderly

Plasma clearance of topiramate is unchanged in elderly subjects in the absence of underlying renal disease.

Renal impairment

The plasma and renal clearance of topiramate decreased in patients with moderate and severe impaired renal function ($\text{CL}_{\text{CR}} < 70 \text{ mL/min}$). As a result, higher steady-state topiramate plasma concentrations are expected for a given dose in renal-impaired patients as compared to those with normal renal function. In addition, patients with renal impairment will require a longer time to reach steady-state at each dose. In patients with moderate and severe renal impairment, half of the usual starting and maintenance dose is recommended (see *Dosage and Administration – Special populations, Renal impairment*).

Topiramate is effectively removed from plasma by hemodialysis. A prolonged period of hemodialysis may cause topiramate concentration to fall below levels that are required to maintain an anti-seizure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of topiramate in the patient being dialyzed.

Hepatic impairment

Plasma clearance of topiramate decreased a mean of 26% in patients with moderate to severe hepatic impairment. Therefore, topiramate should be administered with caution in patients with hepatic impairment.

NON-CLINICAL INFORMATION

Acute and long-term exposure of mice, rats, dogs and rabbits to topiramate was well tolerated. Hyperplasia of the gastric epithelial cells was observed only in rodents and in rats was reversible after 9 weeks without treatment.

Carcinogenicity and Mutagenicity

Tumors of smooth muscle origin in the urinary bladder were seen only in mice (oral dosages up to 300 mg/kg for 21 months) and appear to be unique to the species. Since no human counterpart exists, they were not considered clinically relevant. No such findings occurred in the rat carcinogenicity study (oral dosages up to 120 mg/kg/day for 24 months). Other toxicologic and pathologic effects of topiramate observed in these studies may be related to the weak induction of drug metabolizing enzymes or weak carbonic anhydrase inhibition.

In a battery of *in vitro* and *in vivo* mutagenicity assays, topiramate did not show genotoxic potential.

Reproductive and Developmental Toxicology

In preclinical studies, topiramate has been shown to have teratogenic effects in the species studied (mice, rats and rabbits). In mice, fetal weights and skeletal ossification were reduced at 500 mg/kg/day in conjunction with maternal toxicity. Overall numbers of fetal malformations in mice were increased for all drug-treated groups (20, 100 and 500 mg/kg/day), but no significant differences or dosage-response relationships were observed for overall or specific malformations, suggesting that other factors such as maternal toxicity may be involved.

In rats, dosage-related maternal and embryo/fetal toxicity (reduced fetal weights and/or skeletal ossification) were observed down to 20 mg/kg/day with teratogenic effects (limb and digit defects) at 400 mg/kg/day and above. In rabbits, dosage-related maternal toxicity was noted down to 10 mg/kg/day with embryo/fetal toxicity (increased lethality) down to 35 mg/kg/day, and teratogenic effects (rib and vertebral malformations) at 120 mg/kg/day.

The teratogenic effects seen in rats and rabbits were similar to those seen with carbonic anhydrase inhibitors, which have not been associated with malformations in humans. Effects on growth were also indicated by lower weights at birth and during lactation for pups from female rats treated with 20 or 100 mg/kg/day during gestation and lactation. In rats, topiramate crosses the placental barrier.

In juvenile rats, daily oral administration of topiramate at doses up to 300 mg/kg/day during the period of development corresponding to infancy, childhood, and adolescence resulted in toxicities similar to those in adult animals (decreased food consumption with decreased body weight gain, centrolobular hepatocellular hypertrophy and slight urothelial hyperplasia in the urinary bladder). There were no relevant effects on long bone (tibia) growth or bone (femur) mineral density, preweaning and reproductive development, neurological development (including assessments on memory and learning), mating and fertility or hysterotomy parameters.

Fertility

Despite maternal and paternal toxicity as low as 8 mg/kg/day, no effects on fertility were observed, in male or female rats with up to 100 mg/kg/day.

CLINICAL INFORMATION

Indications

Epilepsy

TOPAMAX® is indicated as monotherapy in patients with newly diagnosed epilepsy or for conversion to monotherapy in patients with epilepsy.

TOPAMAX® is indicated as adjunctive therapy for adults and children aged 2 and above with partial onset seizures or generalized tonic-clonic seizures.

TOPAMAX® is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox Gastaut syndrome.

Migraine

TOPAMAX® is indicated in adults for the prophylaxis of migraine headache. The usefulness of TOPAMAX® in the acute treatment of migraine headache has not been studied.

Dosage and Administration

It is not necessary to monitor topiramate plasma concentrations to optimize therapy with TOPAMAX®. On rare occasions, the addition of TOPAMAX® to phenytoin may require an adjustment of the dose of phenytoin to achieve optimal clinical outcome. Addition or withdrawal of phenytoin and carbamazepine to adjunctive therapy with TOPAMAX® may require adjustment of the dose of TOPAMAX®.

Dosage

It is recommended that therapy be initiated at a low dose followed by titration to an effective dose.

Epilepsy-adjunctive therapy

Adults

Therapy should begin at 25 to 50 mg nightly for one week. Use of lower initial doses has been reported, but has not been studied systematically. Subsequently, at weekly or bi-weekly intervals, the dose should be increased by 25 to 50 [to 100] mg/day and taken in two divided doses. Dose titration should be guided by clinical outcome. Some patients may achieve efficacy with once-a-day dosing.

In clinical trials as adjunctive therapy, 200 mg was effective and was the lowest dosage studied. This is therefore considered the minimum effective dose. The usual daily dose is 200 to 400 mg in two divided doses. Individual patients have received doses as high as 1600 mg/day.

These dosing recommendations apply to all adults, including the elderly, in the absence of underlying renal disease (see section Warnings and Precautions).

Patients with renal impairment

In renally impaired subjects (creatinine clearance less than 70 mL/min/1.73m²), one half of the usual adult dose is recommended. Such patients will require a longer time to reach steady-state at each dose.

Patients undergoing hemodialysis

Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to fall below that required to maintain an anti-seizure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis a supplemental dose of topiramate may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of topiramate in the patient being dialyzed.

Patients with hepatic disease

In hepatically impaired patients topiramate plasma concentrations may be increased. The mechanism is not well understood.

Children aged 2 and above

The recommended total daily dose of TOPAMAX® as adjunctive therapy is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome.

Daily doses up to 30 mg/kg/day have been studied and were generally well tolerated.

Epilepsy-monotherapy

When concomitant antiepileptic drugs (AEDs) are withdrawn to achieve monotherapy with topiramate, consideration should be given to the effects this may have on seizure control. Unless safety concerns

require an abrupt withdrawal of the concomitant AED, a gradual discontinuation at the rate of approximately one-third of the concomitant AED dose every 2 weeks is recommended (*see Warnings and Precautions – Withdrawal of TOPAMAX®*).

When enzyme inducing drugs are withdrawn, topiramate levels will increase. A decrease in TOPAMAX® dosage may be required if clinically indicated.

Adults

Titration should begin at 25 mg nightly for 1 week. The dosage should then be increased at 1- or 2-week intervals by increments of 25 or 50 mg/day, administered in two divided doses. If the patient is unable to tolerate the titration regimen, smaller increments or longer intervals between increments can be used. Dose and titration rate should be guided by clinical outcome.

The recommended initial target dose for topiramate monotherapy in adults is 100 mg/day and the maximum recommended daily dose is 500 mg. Some patients with refractory forms of epilepsy have tolerated topiramate monotherapy at doses of 1,000 mg/day. These dosing recommendations apply to all adults including the elderly in the absence of underlying renal disease.

Children aged 2 and above

Treatment of children aged 2 years and above should begin at 0.5 to 1 mg/kg nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 0.5 to 1 mg/kg/day, administered in two divided doses. If the child is unable to tolerate the titration regimen, smaller increments or longer intervals between dose increments can be used. Dose and dose titration rate should be guided by clinical outcome.

The recommended initial target dose range for topiramate monotherapy in children aged two years and above is 100 to 400 mg/day. Children with recently diagnosed partial onset seizures have received doses of up to 500 mg/day.

Migraine

Adult

The recommended total daily dose of topiramate for prophylaxis of migraine headache is 100 mg/day administered in two divided doses. Titration should begin at 25 mg nightly for 1 week. The dosage should then be increased in increments of 25 mg/day administered at 1-week intervals. If the patient is unable to tolerate the titration regimen, longer intervals between dose adjustments can be used.

Some patients may experience a benefit at a total daily dose of 50 mg/day. Patients have received a total daily dose up to 200 mg/day. Dose and titration rate should be guided by clinical outcome (*see Pharmacodynamic Properties – Migraine clinical trials*).

Special Populations

Renal Impairment

Patients with moderate and severe renal impairment ($CL_{CR} < 70$ mL/min) may require a dose reduction. Half of the usual starting and maintenance dose is recommended (*see Pharmacokinetic Properties – Special populations, Renal impairment*).

Since TOPAMAX® is removed from plasma by hemodialysis, a supplemental dose of TOPAMAX® equal to approximately one-half the daily dose should be administered on hemodialysis days. The supplemental dose should be administered in divided doses at the beginning and completion of the hemodialysis procedure. The supplemental dose may differ based on the characteristics of the dialysis equipment being used (*see Pharmacokinetic Properties – Special populations, Renal impairment*).

Hepatic Impairment

Topiramate should be administered with caution in patients with hepatic impairment (*see Pharmacokinetic Properties – Special populations, Hepatic impairment*).

Administration

TOPAMAX® is available in tablets and a capsule sprinkle formulation for oral administration. It is recommended that TOPAMAX® tablets not be broken. The sprinkle formulation is provided for those patients who cannot swallow tablets, e.g. pediatric and elderly patients.

TOPAMAX® sprinkle capsules may be swallowed whole or may be administered by carefully opening the capsule and sprinkling the entire contents on a small amount (teaspoon) of soft food. This drug/food mixture should be swallowed immediately and not chewed. It should not be stored for future use.

TOPAMAX® can be taken without regard to meals.

Warnings and Precautions

Withdrawal of TOPAMAX®

In patients with or without a history of seizures or epilepsy, AEDs including TOPAMAX® should be gradually withdrawn to minimize the potential for seizures or increased seizure frequency. In clinical trials, daily dosages were decreased in weekly intervals by 50 to 100 mg in adults with epilepsy and by 25 to 50 mg in adults receiving TOPAMAX® at doses up to 100 mg/day for migraine prophylaxis. In clinical trials of children, TOPAMAX® was gradually withdrawn over a 2 to 8 week period. In situations where rapid withdrawal of TOPAMAX® is medically required, appropriate monitoring is recommended.

Renal impairment

The major route of elimination of unchanged topiramate and its metabolites is via the kidney. Renal elimination is dependent on renal function and is independent of age. Patients with moderate or severe renal impairment may take 10 to 15 days to reach steady-state plasma concentrations as compared to 4 to 8 days in patients with normal renal function.

As with all patients, the titration schedule should be guided by clinical outcome (i.e., seizure control, avoidance of side effects) with the knowledge that subjects with known renal impairment may require a longer time to reach steady-state at each dose (see *Dosage and Administration – Special Populations, Renal impairment and Pharmacokinetic Properties – Special populations, Renal impairment*).

Hydration

Oligohidrosis (decreased sweating) and anhidrosis have been reported in association with the use of topiramate. Decreased sweating and hyperthermia (rise in body temperature) may occur especially in young children exposed to high ambient temperatures (see section *Adverse Reactions*).

Adequate hydration while using topiramate is very important. Hydration can reduce the risk of nephrolithiasis (see *Warnings and Precautions - Nephrolithiasis*). Proper hydration prior to and during activities such as exercise or exposure to warm temperatures may reduce the risk of heat-related adverse events (see *Adverse Reactions*).

Mood disturbances/depression

An increased incidence of mood disturbances and depression has been observed during topiramate treatment.

Suicide/suicidal ideation

AEDs, including TOPAMAX®, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. A meta-analysis of randomized placebo-controlled trials of AEDs has shown an increased risk of suicidal ideation and behaviour (0.43% on AEDs versus 0.24% on placebo). The mechanism of this risk is not known.

In double-blind clinical trials, suicide related events (suicidal ideation, suicide attempts, and suicide) occurred at a frequency of 0.5% in topiramate treated patients (46 out of 8,652 patients treated) compared to 0.2% treated with placebo (8 out of 4,045 patients treated). One completed suicide was reported in a bipolar disorder double-blind trial in a patient on topiramate.

Patients therefore should be monitored for signs of suicidal ideation and behaviour and appropriate treatment should be considered. Patients (and, when appropriate, caregivers of patients) should be advised to seek immediate medical advice should signs of suicidal ideation or behaviour emerge.

Serious skin reactions

Serious skin reactions (Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)) have been reported in patients receiving TOPAMAX (see *Adverse Reactions*). The majority of cases have occurred in patients concurrently taking other medications that are known to be associated with SJS and TEN. There have also been several cases in patients receiving monotherapy. It is recommended that patients be informed about the signs of serious skin reactions. If SJS or TEN are suspected, use of TOPAMAX should be discontinued.

Nephrolithiasis

Some patients, especially those with a predisposition to nephrolithiasis, may be at increased risk for renal stone formation and associated signs and symptoms such as renal colic, renal pain or flank pain.

Risk factors for nephrolithiasis include prior stone formation, a family history of nephrolithiasis and hypercalciuria (see *Warnings and Precautions – Metabolic acidosis and sequelae*). None of these risk factors can reliably predict stone formation during topiramate treatment. In addition, patients taking other medication associated with nephrolithiasis may be at increased risk (see *Interactions – Other forms of interactions, Agents predisposing to nephrolithiasis*).

Hepatic impairment

In hepatically-impaired patients, topiramate should be administered with caution as the clearance of topiramate may be decreased (see *Dosage and Administration – Special Populations, Hepatic impairment and Pharmacokinetic Properties – Special populations, Hepatic impairment*).

Acute myopia and secondary angle closure glaucoma syndrome

A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving TOPAMAX®. Symptoms include acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include some or all of the following: myopia, mydriasis, anterior chamber shallowing, ocular hyperemia (redness), choroidal detachments, retinal pigment epithelial detachments, macular striae, and increased intraocular pressure. This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating TOPAMAX® therapy. In contrast to primary narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with topiramate has been reported in pediatric patients as well as adults. Treatment includes discontinuation of TOPAMAX®, as rapidly as possible in the judgment of the treating physician, and appropriate measures to reduce intraocular pressure. These measures generally result in a decrease in intraocular pressure.

Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss.

Visual field defects

Visual field defects have been reported in patients receiving topiramate independent of elevated intraocular pressure. In clinical trials, most of these events were reversible after topiramate discontinuation. If visual problems occur at any time during topiramate treatment, consideration should be given to discontinuing the drug.

Metabolic acidosis and sequelae

Hyperchloremic, non-anion gap, metabolic acidosis (i.e. decreased serum bicarbonate below the normal reference range in the absence of respiratory alkalosis) is associated with topiramate treatment. This decrease in serum bicarbonate is due to the inhibitory effect of topiramate on renal carbonic anhydrase. Generally, the decrease in bicarbonate occurs early in treatment although it can occur at any time during treatment. These decreases are usually mild to moderate (average decrease of 4 mmol/L at doses of 100 mg/day or above in adults and at approximately 6 mg/kg/day in pediatric patients. Rarely, patients have experienced decreases to values below 10 mmol/L. Conditions or therapies that predispose to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, surgery, ketogenic diet, or certain drugs) may be additive to the bicarbonate lowering effects of topiramate.

Chronic, untreated metabolic acidosis may increase the risk of nephrolithiasis or nephrocalcinosis (see *Warnings and Precautions – Nephrolithiasis*).

Chronic metabolic acidosis in pediatric patients can reduce growth rates. The effect of topiramate on growth and bone-related sequelae has not been systematically investigated in adult populations. A one year, open-label study in pediatric patients aged 6 to 15 years including 63 subjects with recent or new onset of epilepsy was conducted to assess the effects of topiramate (28 subjects) versus levetiracetam on growth, development, and bone mineralization. Continued growth was observed in both treatment groups but the topiramate group showed statistically significant reductions in mean annual change from baseline in body weight and bone mineral density compared to the levetiracetam group. A similar trend was also observed for height and height velocity but were not statistically significant. Growth-related changes were not clinically significant nor treatment limiting. Other confounding factors cannot be excluded.

Depending on underlying conditions, appropriate evaluation including serum bicarbonate levels is recommended with topiramate therapy. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering).

Hyperammonemia and encephalopathy

Hyperammonemia with or without encephalopathy has been reported with topiramate treatment (see *Adverse Reactions*). The risk for hyperammonemia with topiramate appears dose-related. Hyperammonemia has been reported more frequently when topiramate is used concomitantly with valproic acid (see *Interactions*).

Clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy. In most cases, hyperammonemic encephalopathy abated with discontinuation of treatment. In patients who develop unexplained lethargy, or changes in mental status associated with topiramate monotherapy or adjunctive therapy, it is recommended to consider hyperammonemic encephalopathy and measuring ammonia levels.

Women of childbearing potential

TOPAMAX® may cause fetal harm when administered to a pregnant woman. There is an increased risk of pre-term labor and premature delivery associated with the use of AEDs, including topiramate.

Before the initiation of treatment with topiramate in a woman of childbearing potential, pregnancy testing should be performed and a highly effective contraceptive method used. The patient should be fully informed of the risks related to the use of topiramate during pregnancy (see *Pregnancy and Breast Feeding*).

For migraine prophylaxis, TOPAMAX® is contraindicated in pregnancy and in women of childbearing potential if a highly effective method of contraception is not used (see *Contraindications and Interactions*).

TOPAMAX® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (see *Contraindications, Pregnancy and Breast Feeding*).

Nutritional supplementation

A dietary supplement or increased food intake may be considered if the patient is losing weight while on this medication.

Carcinogenesis, mutagenesis, impairment of fertility

An increase in urinary bladder tumors was observed in mice given topiramate (20, 75, and 300 mg/kg) in the diet for 21 months. The elevated bladder tumor incidence, which was statistically significant in males and females receiving 300 mg/kg, was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. Plasma exposures in mice receiving 300 mg/kg were approximately 0.5 to 1 times steady state exposures measured in patients receiving topiramate monotherapy at the recommended human dose (RHD) of 400 mg, and 1.5 to 2 times steady state topiramate exposures in patients receiving 400 mg of topiramate plus phenytoin. The relevance of this finding to human carcinogenic risk is uncertain. No evidence of carcinogenicity was seen in rats following oral administration of topiramate for 2 years at doses up to 120 mg/kg (approximately 3 times the RHD on a mg/m² basis).

Topiramate did not demonstrate genotoxic potential when tested in a battery of in vitro and in vivo assays. Topiramate was not mutagenic in the Ames test or the in vitro mouse lymphoma assay; it did not increase

unscheduled DNA synthesis in rat hepatocytes in vitro; and it did not increase chromosomal aberrations in human lymphocytes in vitro or in rat bone marrow in vivo.

No adverse effects on male or female fertility were observed in rats at doses up to 100 mg/kg (2.5 times the RHD on a mg/m² basis).

Labor and delivery

In studies of rats where dams were allowed to deliver pups naturally, no drug-related effects on gestation length or parturition were observed at dosage levels up to 200 mg/kg/day.

The effect of TOPAMAX® (topiramate) on labor and delivery in humans is unknown.

Pediatric use

Safety and effectiveness in children below 2 years have not been established. The pharmacokinetic profile of TOPAMAX® was studied in patients between the ages of 4 and 17 years.

Geriatric use

In clinical trials, 2% of patients were over 60. No age related difference in effectiveness or adverse effects were seen. There were no pharmacokinetic differences related to age alone, although the possibility of age-associated renal functional abnormalities should be considered.

Race and gender effects

Evaluation of efficacy and safety in clinical trials has shown no race or gender related effects.

Adverse Reactions

Throughout this section, adverse reactions are presented. Adverse reactions are adverse events that were considered to be reasonably associated with the use of topiramate based on the comprehensive assessment of the available adverse event information. A causal relationship with topiramate cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Clinical trial data

The safety of TOPAMAX® was evaluated from a clinical trial database consisting of 4111 patients (3182 on TOPAMAX® and 929 on placebo) who participated in 20 double-blind trials and 2847 patients who participated in 34 open-label trials, respectively, for the treatment of primary generalized tonic-clonic seizures, partial onset seizures, seizures associated with Lennox-Gastaut syndrome, newly or recently diagnosed epilepsy or migraine. The information presented in this section was derived from pooled data.

The majority of all adverse reactions were mild to moderate in severity.

Double-blind, placebo-controlled data, adjunctive epilepsy trials – adult patients

Adverse reactions reported in ≥1% of TOPAMAX®-treated adult patients in double-blind, placebo-controlled adjunctive epilepsy trials are shown in Table 1. Adverse reactions that had an incidence >5% in the recommended dose range (200 to 400 mg/day) in adults in double-blind, placebo-controlled adjunctive epilepsy studies in descending order of frequency included somnolence, dizziness, fatigue, irritability, weight decreased, bradyphrenia, paresthesias, diplopia, coordination abnormal, nausea, nystagmus, lethargy, anorexia, dysarthria, vision blurred, decreased appetite, memory impairment and diarrhea.

Table 1: Adverse Reactions Reported by ≥1% of TOPAMAX® -Treated Adult Patients in Double-Blind, Placebo-Controlled, Adjunctive Epilepsy Trials

| System/Organ Class Adverse Reaction | TOPAMAX® 200-400 mg/day (N=354) | TOPAMAX® 600-1000 mg/day (N=37) | PLACEBO (N=38) |
|---|---------------------------------------|---------------------------------------|-------------------|
| | % | % | % |
| Metabolism and Nutrition Disorders | | | |
| Anorexia | 5.4 | 6.2 | 1.8 |
| Decreased appetite | 5.1 | 8.7 | 3.7 |
| Psychiatric Disorders | | | |
| Bradyphrenia | 8.2 | 19.5 | 3.1 |

Table 1: Adverse Reactions Reported by ≥1% of TOPAMAX® -Treated Adult Patients in Double-Blind, Placebo-Controlled, Adjunctive Epilepsy Trials

| System/Organ Class Adverse Reaction | TOPAMAX® 200-400 mg/day (N=354) % | TOPAMAX® 600-1000 mg/day (N=37) % | PLACEBO (N=38) % |
|---|--|--|------------------------|
| Expressive language disorder | 4.5 | 9.4 | 1.6 |
| Confusional state | 3.1 | 5.0 | 0.8 |
| Depression | 3.1 | 11.7 | 3.4 |
| Insomnia | 3.1 | 6.4 | 4.5 |
| Aggression | 2.8 | 3.2 | 1.8 |
| Agitation | 1.7 | 2.3 | 1.3 |
| Anger | 1.7 | 2.1 | 0.5 |
| Anxiety | 1.7 | 6.6 | 2.9 |
| Disorientation | 1.7 | 3.2 | 1.0 |
| Mood altered | 1.7 | 4.6 | 1.0 |
| Nervous System Disorders | | | |
| Somnolence | 17.8 | 17.4 | 8.4 |
| Dizziness | 16.4 | 34.1 | 13.6 |
| Paresthesia | 8.2 | 17.2 | 3.7 |
| Coordination abnormal | 7.1 | 11.4 | 4.2 |
| Nystagmus | 6.2 | 11.7 | 6.8 |
| Lethargy | 5.6 | 8.0 | 2.1 |
| Dysarthria | 5.4 | 6.2 | 1.0 |
| Memory impairment | 5.1 | 10.8 | 1.8 |
| Disturbance in attention | 4.5 | 11.9 | 1.8 |
| Tremor | 4.0 | 9.4 | 5.0 |
| Amnesia | 3.4 | 5.3 | 1.0 |
| Balance disorder | 3.4 | 3.9 | 2.4 |
| Hypoesthesia | 3.1 | 5.9 | 1.0 |
| Intention tremor | 3.1 | 4.8 | 2.9 |
| Dysgeusia | 1.4 | 4.3 | 0.8 |
| Mental impairment | 1.4 | 5.0 | 1.3 |
| Speech disorder | 1.1 | 2.7 | 0.5 |
| Eye Disorders | | | |
| Diplopia | 7.3 | 12.1 | 5.0 |
| Vision blurred | 5.4 | 8.9 | 2.4 |
| Visual disturbance | 2.0 | 1.4 | 0.3 |
| Gastrointestinal Disorders | | | |
| Nausea | 6.8 | 15.1 | 8.4 |
| Diarrhea | 5.1 | 14.0 | 5.2 |
| Abdominal pain upper | 3.7 | 3.9 | 2.1 |
| Constipation | 3.7 | 3.2 | 1.8 |
| Stomach discomfort | 3.1 | 3.2 | 1.3 |
| Dyspepsia | 2.3 | 3.0 | 2.1 |
| Dry mouth | 1.7 | 3.7 | 0.3 |
| Abdominal pain | 1.1 | 2.7 | 0.8 |
| Musculoskeletal and Connective Tissue Disorders | | | |
| Myalgia | 2.0 | 2.5 | 1.3 |
| Muscle spasms | 1.7 | 2.1 | 0.8 |
| Musculoskeletal chest pain | 1.1 | 1.8 | 0.3 |
| General Disorders and Administration Site Conditions | | | |
| Fatigue | 13.0 | 30.7 | 11.8 |
| Irritability | 9.3 | 14.6 | 3.7 |
| Asthenia | 3.4 | 3.0 | 1.8 |
| Gait disturbance | 1.4 | 2.5 | 1.3 |
| Investigations | | | |
| Weight decreased | 9.0 | 11.9 | 4.2 |

The recommended dose for adjunctive epilepsy therapy in adults is 200-400 mg/day.

Double-blind, placebo-controlled data, adjunctive epilepsy trials – pediatric patients

Adverse reactions reported in >2% of TOPAMAX®-treated pediatric patients (2 to 16 years of age) in double-blind, placebo-controlled adjunctive epilepsy trials are shown in Table 2. Adverse reactions that

had an incidence >5% in the recommended dose range (5 to 9 mg/kg/day) in descending order of frequency included decreased appetite, fatigue, somnolence, lethargy, irritability, disturbance in attention, weight decreased, aggression, rash, abnormal behavior, anorexia, balance disorder, and constipation.

Table 2: Adverse Reactions Reported by ≥2% of TOPAMAX®-Treated Pediatric Patients in Double-Blind, Placebo-Controlled, Adjunctive Epilepsy Trials

| System/Organ Class | Topamax (N=104) | PLACEBO (N=102) |
|---|--------------------|--------------------|
| Adverse Reaction | % | % |
| Metabolism and Nutrition Disorders | | |
| Decreased appetite | 19.2 | 12.7 |
| Anorexia | 5.8 | 1.0 |
| Psychiatric Disorders | | |
| Aggression | 8.7 | 6.9 |
| Abnormal behavior | 5.8 | 3.9 |
| Confusional state | 2.9 | 2.0 |
| Mood altered | 2.9 | 2.0 |
| Nervous System Disorders | | |
| Somnolence | 15.4 | 6.9 |
| Lethargy | 13.5 | 8.8 |
| Disturbance in attention | 10.6 | 2.0 |
| Balance disorder | 5.8 | 2.0 |
| Dizziness | 4.8 | 2.9 |
| Memory impairment | 3.8 | 1.0 |
| Respiratory, Thoracic and Mediastinal Disorders | | |
| Epistaxis | 4.8 | 1.0 |
| Gastrointestinal Disorders | | |
| Constipation | 5.8 | 4.9 |
| Skin and Subcutaneous Tissue Disorders | | |
| Rash | 6.7 | 5.9 |
| General Disorders and Administration Site Conditions | | |
| Fatigue | 16.3 | 4.9 |
| Irritability | 11.5 | 8.8 |
| Gait disturbance | 4.8 | 2.0 |
| Investigations | | |
| Weight decreased | 9.6 | 1.0 |

The recommended dose for adjunctive epilepsy therapy in children (2-16 years of age) is 5 to 9 mg/kg/day.

Double-blind, controlled data, monotherapy epilepsy trials – adult patients

Adverse reactions reported in ≥1% of TOPAMAX®-treated adult patients in double-blind, controlled monotherapy epilepsy trials are shown in Table 3. Adverse reactions that had an incidence >5% at the recommended dose (400 mg/day) in descending order of frequency included paresthesia, weight decreased, fatigue, anorexia, depression, memory impairment, anxiety, diarrhea, asthenia, dysgeusia, and hypoesthesia.

Table 3: Adverse Reactions Reported by ≥1% of TOPAMAX®-Treated Adult Patients in Double-Blind, Controlled Monotherapy Epilepsy Trials

| System/Organ Class | TOPAMAX®- 50 mg/day (N=257) | TOPAMAX®- 400 mg/day (N=153) |
|---|-----------------------------------|------------------------------------|
| Adverse Reaction | % | % |
| Blood and Lymphatic System Disorders | | |
| Anemia | 0.8 | 2.0 |
| Metabolism and Nutrition Disorders | | |
| Anorexia | 3.5 | 12.4 |
| Decreased appetite | 2.3 | 2.6 |
| Psychiatric Disorders | | |
| Depression | 4.3 | 8.5 |

Table 3: Adverse Reactions Reported by ≥1% of TOPAMAX®-Treated Adult Patients in Double-Blind, Controlled Monotherapy Epilepsy Trials

| System/Organ Class | TOPAMAX®- 50 mg/day (N=257) | TOPAMAX®- 400 mg/day (N=153) |
|---|--|---|
| Adverse Reaction | % | % |
| Anxiety | 3.9 | 6.5 |
| Bradypnea | 2.3 | 4.6 |
| Expressive language disorder | 3.5 | 4.6 |
| Depressed mood | 0.8 | 2.6 |
| Mood altered | 0.4 | 2.0 |
| Mood swings | 1.6 | 2.0 |
| Nervous System Disorders | | |
| Paresthesia | 18.7 | 40.5 |
| Memory impairment | 1.2 | 7.2 |
| Dysgeusia | 2.3 | 5.9 |
| Hypoesthesia | 4.3 | 5.2 |
| Balance disorder | 1.6 | 3.3 |
| Dysarthria | 1.6 | 2.6 |
| Cognitive disorder | 0.4 | 2.0 |
| Lethargy | 1.2 | 2.0 |
| Mental impairment | 0.8 | 2.0 |
| Psychomotor skills impaired | 0 | 2.0 |
| Sedation | 0 | 1.3 |
| Visual field defect | 0.4 | 1.3 |
| Eye Disorders | | |
| Dry eye | 0 | 1.3 |
| Ear and Labyrinth Disorders | | |
| Ear pain | 0 | 1.3 |
| Tinnitus | 1.6 | 1.3 |
| Respiratory, Thoracic and Mediastinal Disorders | | |
| Dyspnea | 1.2 | 2.0 |
| Rhinorrhea | 0 | 1.3 |
| Gastrointestinal Disorders | | |
| Diarrhea | 5.4 | 6.5 |
| Paresthesia oral | 1.2 | 3.3 |
| Dry mouth | 0.4 | 2.6 |
| Gastritis | 0.8 | 2.6 |
| Abdominal pain | 1.2 | 2.0 |
| Gastroesophageal reflux disease | 0.4 | 2.0 |
| Gingival bleeding | 0 | 1.3 |
| Skin and Subcutaneous Tissue Disorders | | |
| Rash | 0.4 | 3.9 |
| Alopecia | 1.6 | 3.3 |
| Pruritus | 0.4 | 3.3 |
| Hypoesthesia facial | 0.4 | 2.0 |
| Pruritus generalized | 0 | 1.3 |
| Musculoskeletal and Connective Tissue Disorders | | |
| Muscle spasms | 2.7 | 3.3 |
| Arthralgia | 1.9 | 2.0 |
| Muscle twitching | 0.4 | 1.3 |
| Renal and Urinary Disorders | | |
| Nephrolithiasis | 0 | 2.6 |
| Dysuria | 0.8 | 2.0 |
| Pollakiuria | 0.8 | 2.0 |
| Reproductive System and Breast Disorders | | |
| Erectile dysfunction | 0.8 | 1.3 |
| General Disorders and Administration Site Conditions | | |
| Fatigue | 15.2 | 14.4 |
| Asthenia | 3.5 | 5.9 |
| Irritability | 3.1 | 3.3 |
| Investigations | | |

Table 3: Adverse Reactions Reported by $\geq 1\%$ of TOPAMAX®-Treated Adult Patients in Double-Blind, Controlled Monotherapy Epilepsy Trials

| System/Organ Class Adverse Reaction | TOPAMAX®- 50 mg/day (N=257) % | TOPAMAX®- 400 mg/day (N=153) % |
|--|--|---|
| Weight decreased | 7.0 | 17.0 |

The recommended dose for monotherapy therapy in adults is 400 mg/day.

Double-blind, controlled data, monotherapy epilepsy trials – pediatric patients

Adverse reactions reported in $\geq 2\%$ of TOPAMAX®-treated pediatric patients (10 to 16 years of age) in double-blind, controlled monotherapy epilepsy trials are shown in Table 4. Adverse reactions that had an incidence $>5\%$ at the recommended dose (400 mg/day) in descending order of frequency included weight decreased, paresthesia, diarrhea, disturbance in attention, pyrexia, and alopecia.

Table 4: Adverse Reactions Reported by $\geq 2\%$ of TOPAMAX®-Treated Pediatric Patients in Double-Blind, Controlled Monotherapy Epilepsy Trials

| System/Organ Class Adverse Reaction | TOPAMAX® 50 mg/day (N=77) % | TOPAMAX® 400 mg/day (N=63) % |
|---|--------------------------------------|---------------------------------------|
| Metabolism and Nutrition Disorders | | |
| Decreased appetite | 1.3 | 4.8 |
| Psychiatric Disorders | | |
| Bradyphrenia | 0 | 4.8 |
| Mood altered | 1.3 | 4.8 |
| Depression | 0 | 3.2 |
| Nervous System Disorders | | |
| Paresthesia | 3.9 | 15.9 |
| Disturbance in attention | 3.9 | 7.9 |
| Ear and Labyrinth Disorders | | |
| Vertigo | 0 | 3.2 |
| Respiratory, Thoracic and Mediastinal Disorders | | |
| Epistaxis | 0 | 3.2 |
| Gastrointestinal Disorders | | |
| Diarrhea | 3.9 | 9.5 |
| Vomiting | 3.9 | 4.8 |
| Skin and Subcutaneous Tissue Disorders | | |
| Alopecia | 0 | 6.3 |
| General Disorders and Administration Site Conditions | | |
| Pyrexia | 0 | 6.3 |
| Asthenia | 0 | 4.8 |
| Investigations | | |
| Weight decreased | 7.8 | 20.6 |
| Social Circumstances | | |
| Learning disability | 0 | 3.2 |

The recommended dose for monotherapy therapy in children 10 years and older is 400 mg/day.

Double-blind, placebo-controlled data, migraine prophylaxis trials – adult patients

Adverse reactions reported in $\geq 1\%$ of TOPAMAX®-treated adult patients in double-blind, placebo-controlled migraine prophylaxis trials are shown in Table 5. Adverse reactions that had an incidence $>5\%$ at the recommended dose (100 mg/day) in descending order of frequency included paresthesia, fatigue, nausea, diarrhea, weight decreased, dysgeusia, anorexia, decreased appetite, insomnia, hypoesthesia, disturbance in attention, anxiety, somnolence, and expressive language disorder.

Table 5: Adverse Reactions Reported by $\geq 1\%$ of TOPAMAX®-Treated Adult Patients in Double-Blind, Placebo-Controlled Migraine Prophylaxis Trials

| System/Organ Class Adverse Reaction | TOPAMAX® 50 mg/day (N=227) % | TOPAMAX® 100 mg/day (N=374) % | TOPAMAX® 200 mg/day (N=501) % | PLACEBO (N=436) % |
|---|---------------------------------------|--|--|-------------------------|
| Metabolism and Nutrition Disorders | | | | |
| Anorexia | 3.5 | 7.5 | 7.2 | 3.0 |
| Decreased appetite | 5.7 | 7.0 | 6.8 | 3.0 |
| Psychiatric Disorders | | | | |
| Insomnia | 4.8 | 7.0 | 5.6 | 3.9 |
| Anxiety | 4.0 | 5.3 | 5.0 | 1.8 |
| Expressive language disorder | 6.6 | 5.1 | 5.2 | 1.4 |
| Depression | 3.5 | 4.8 | 7.4 | 4.1 |
| Depressed mood | 0.4 | 2.9 | 2.0 | 0.9 |
| Confusional state | 0.4 | 1.6 | 2.0 | 1.1 |
| Mood swings | 1.8 | 1.3 | 1.0 | 0.2 |
| Affect lability | 0.4 | 1.1 | 0.2 | 0.2 |
| Bradyphrenia | 1.8 | 1.1 | 3.4 | 1.4 |
| Nervous System Disorders | | | | |
| Paresthesia | 35.7 | 50.0 | 48.5 | 5.0 |
| Dysgeusia | 15.4 | 8.0 | 12.6 | 0.9 |
| Hypoesthesia | 5.3 | 6.7 | 7.4 | 1.4 |
| Disturbance in attention | 2.6 | 6.4 | 9.2 | 2.3 |
| Somnolence | 6.2 | 5.1 | 6.8 | 3.0 |
| Memory impairment | 4.0 | 4.5 | 6.2 | 1.6 |
| Amnesia | 3.5 | 2.9 | 5.2 | 0.5 |
| Tremor | 1.3 | 1.9 | 2.4 | 1.4 |
| Balance disorder | 0.4 | 1.3 | 0.4 | 0 |
| Mental impairment | 0.4 | 1.1 | 1.8 | 0.9 |
| Eye Disorders | | | | |
| Vision blurred | 4.0 | 2.4 | 4.4 | 2.5 |
| Ear and Labyrinth Disorders | | | | |
| Tinnitus | 0.4 | 1.3 | 1.6 | 0.7 |
| Respiratory, Thoracic and Mediastinal Disorders | | | | |
| Dyspnea | 1.3 | 2.7 | 1.6 | 1.4 |
| Epistaxis | 0.4 | 1.1 | 0.6 | 0.5 |
| Gastrointestinal Disorders | | | | |
| Nausea | 9.3 | 13.6 | 14.6 | 8.3 |
| Diarrhea | 9.3 | 11.2 | 10.0 | 4.4 |
| Dry mouth | 1.8 | 3.2 | 5.0 | 2.5 |
| Paresthesia oral | 1.3 | 2.9 | 1.6 | 0.5 |
| Constipation | 1.8 | 2.1 | 1.8 | 1.4 |
| Abdominal distension | 0 | 1.3 | 0.2 | 0.2 |
| Stomach discomfort | 2.2 | 1.3 | 1.0 | 0.2 |
| Gastroesophageal reflux disease | 0.4 | 1.1 | 1.2 | 0.5 |
| Musculoskeletal and Connective Tissue Disorders | | | | |
| Muscle twitching | 1.8 | 1.3 | 1.8 | 0.7 |
| General Disorders and Administration Site Conditions | | | | |
| Fatigue | 15.0 | 15.2 | 19.2 | 11.2 |
| Asthenia | 0.9 | 2.1 | 2.6 | 0.5 |
| Irritability | 3.1 | 1.9 | 2.4 | 0.9 |
| Thirst | 1.3 | 1.6 | 1.0 | 0.5 |
| Investigations | | | | |
| Weight decreased | 5.3 | 9.1 | 10.8 | 1.4 |

The recommended dose for migraine prophylaxis is 100 mg/day.

Other clinical trial data

Adverse reactions reported in double-blind controlled clinical trials in $<1\%$ of TOPAMAX®-treated adult patients or at any rate in open-label clinical trials of TOPAMAX®-treated adult patients are shown in Table 6.

Table 6. Adverse Reactions Reported in Double-Blind Controlled Clinical Trials in <1% of TOPAMAX®-Treated Adult Patients or at Any Rate in Open-Label Clinical Trials of TOPAMAX®-Treated Adult Patients

| |
|--|
| <p>Blood and Lymphatic System Disorders Leukopenia, lymphadenopathy, thrombocytopenia</p> <p>Immune System Disorders Hypersensitivity</p> <p>Metabolism and Nutrition Disorders Acidosis hyperchloremic, hypokalemia, increased appetite, metabolic acidosis, polydipsia</p> <p>Psychiatric Disorders Abnormal behavior, anorgasmia, apathy, crying, distractibility, disturbance in sexual arousal, dysphemia, early morning awakening, elevated mood, euphoric mood, flat affect, hallucination, hallucination-auditory, hallucination-visual, hypomania, initial insomnia, lack of spontaneous speech, libido decreased, listless, loss of libido, mania, middle insomnia, orgasmic sensation decreased, panic attack, panic disorder, panic reaction, paranoia, perseveration, reading disorder, restlessness, sleep disorder, suicidal ideation, suicide attempt, tearfulness, thinking abnormal</p> <p>Nervous System Disorders Ageusia, akinesia, anosmia, aphasia, apraxia, aura, burning sensation, cerebellar syndrome, circadian rhythm sleep disorder, clumsiness, complex partial seizure, convulsion, depressed level of consciousness, dizziness postural, drooling, dysesthesia, dysgraphia, dyskinesia, dysphasia, dystonia, essential tremor, formication, grand mal convulsion, hyperesthesia, hypersomnia, hypogeusia, hypokinesia, hyposmia, neuropathy peripheral, parosmia, poor quality sleep, presyncope, repetitive speech, sensory disturbance, sensory loss, stupor, syncope, unresponsive to stimuli</p> <p>Eye Disorders Accommodation disorder, altered visual depth perception, amblyopia, blepharospasm, blindness transient, blindness unilateral, glaucoma, lacrimation increased, mydriasis, night blindness, photopsia, presbyopia, scintillating scotoma, scotoma, visual acuity reduced</p> <p>Ear and Labyrinth Disorders Deafness, deafness neurosensory, deafness unilateral, ear discomfort, hearing impaired</p> <p>Cardiac Disorders Bradycardia, sinus bradycardia, palpitations</p> <p>Vascular Disorders Flushing, hot flush, orthostatic hypotension, Raynaud's phenomenon</p> <p>Respiratory, Thoracic, and Mediastinal Disorders Dysphonia, dyspnea exertional, nasal congestion, paranasal sinus hypersecretion</p> <p>Gastrointestinal Disorders Abdominal discomfort, abdominal pain lower, abdominal tenderness, breath odour, epigastric discomfort, flatulence, glossodynia, hypoesthesia oral, oral pain, pancreatitis, salivary hypersecretion</p> <p>Skin and Subcutaneous Tissue Disorders Anhidrosis, dermatitis allergic, erythema, rash macular, skin discolouration, skin odour abnormal, swelling face, urticaria, urticaria localized</p> <p>Musculoskeletal and Connective Tissue Disorders Flank pain, muscle fatigue, muscular weakness, musculoskeletal stiffness</p> <p>Renal and Urinary Disorders Calculus ureteric, calculus urinary, hematuria, incontinence, micturition urgency, renal colic, renal pain, urinary incontinence</p> <p>Reproductive System and Breast Disorders Sexual dysfunction</p> <p>General Disorders Face edema, feeling abnormal, feeling drunk, feeling jittery, malaise, peripheral coldness, sluggishness</p> <p>Investigations Blood bicarbonate decreased, crystal urine present, tandem gait test abnormal, white blood cell count decreased</p> |
|--|

Adverse reactions reported in double-blind controlled clinical trials in <2% of TOPAMAX®-treated pediatric patients or at any rate in open-label clinical trials of TOPAMAX®-treated pediatric patients are shown in Table 7.

Table 7. Adverse Reactions Reported in Double-Blind Controlled Clinical Trials in <2% of TOPAMAX®-Treated Pediatric Patients or at Any Rate in Open-Label Clinical Trials of TOPAMAX®-Treated Pediatric Patients

| |
|---|
| <p>Blood and Lymphatic System Disorders Eosinophilia, leukopenia, lymphadenopathy, thrombocytopenia</p> <p>Immune System Disorders Hypersensitivity</p> <p>Metabolism and Nutrition Disorders Acidosis hyperchloremic, hypokalemia, increased appetite</p> |
|---|

Table 7. Adverse Reactions Reported in Double-Blind Controlled Clinical Trials in <2% of TOPAMAX®-Treated Pediatric Patients or at Any Rate in Open-Label Clinical Trials of TOPAMAX®-Treated Pediatric Patients

| |
|---|
| Psychiatric Disorders |
| Anger, apathy, crying, distractibility, expressive language disorder, initial insomnia, insomnia, middle insomnia, mood swings, perseveration, sleep disorder, suicidal ideation, suicide attempt |
| Nervous System Disorders |
| Circadian rhythm sleep disorder, convulsion, dysarthria, dysgeusia, grand mal convulsion, hypoesthesia, mental impairment, nystagmus, parosmia, poor quality sleep, psychomotor hyperactivity, psychomotor skills impaired, syncope, tremor |
| Eye Disorders |
| Diplopia, lacrimation increased, vision blurred |
| Ear and Labyrinth Disorders |
| Ear pain |
| Cardiac Disorders |
| Palpitations, sinus bradycardia |
| Vascular Disorders |
| Orthostatic hypotension |
| Respiratory, Thoracic, and Mediastinal Disorders |
| Nasal congestion, paranasal sinus hypersecretion, rhinorrhea |
| Gastrointestinal Disorders |
| Abdominal discomfort, abdominal pain, dry mouth, flatulence, gastritis, gastroesophageal reflux disease, gingival bleeding, glossodynia, pancreatitis, paresthesia oral, stomach discomfort |
| Musculoskeletal and Connective Tissue Disorders |
| Arthralgia, musculoskeletal stiffness, myalgia |
| Renal and Urinary Disorders |
| Incontinence, micturition urgency, pollakiuria |
| General Disorders |
| Feeling abnormal, hyperthermia, malaise, sluggishness |

Postmarketing data

Adverse events first identified as adverse reactions during postmarketing experience with TOPAMAX® are included in Tables 8. In the table, the frequencies are provided according to the following convention:

| | |
|-------------|---------------------------------------|
| Very common | ≥1/10 |
| Common | ≥1/100 to <1/10 |
| Uncommon | ≥1/1,000 to <1/100 |
| Rare | ≥1/10,000 to <1/1,000 |
| Very rare | <1/10,000, including isolated reports |

In Table 8, Adverse reactions are presented by frequency category based on spontaneous reporting rates.

Table 8: Adverse Reactions Identified During Postmarketing Experience with TOPAMAX® by Frequency Category Estimated from Spontaneous Reporting Rates

| | |
|--|-------------------------------|
| Infections and Infestations | |
| <i>Very rare</i> | Nasopharyngitis |
| Blood and Lymphatic System Disorders | |
| <i>Very rare</i> | Neutropenia |
| Immune System Disorders | |
| <i>Very rare</i> | Allergic edema |
| Metabolism and Nutrition Disorders | |
| <i>Very rare</i> | Hyperammonemia |
| <i>Very rare</i> | Hyperammonemic encephalopathy |
| Psychiatric Disorders | |
| <i>Very rare</i> | Feeling of despair |
| Eye Disorders | |
| <i>Very rare</i> | Abnormal sensation in eye |
| <i>Very rare</i> | Angle closure glaucoma |
| <i>Very rare</i> | Conjunctival edema |
| <i>Very rare</i> | Eye movement disorder |
| <i>Very rare</i> | Eyelid edema |
| <i>Very rare</i> | Maculopathy |
| <i>Very rare</i> | Myopia |
| Respiratory, Thoracic and Mediastinal Disorders | |

Table 8: Adverse Reactions Identified During Postmarketing Experience with TOPAMAX® by Frequency Category Estimated from Spontaneous Reporting Rates

| | |
|--|----------------------------|
| Very rare | Cough |
| Skin and Subcutaneous Tissue Disorders | |
| Very rare | Erythema multiforme |
| Very rare | Periorbital edema |
| Very rare | Stevens-Johnson syndrome |
| Very rare | Toxic epidermal necrolysis |
| Musculoskeletal and Connective Tissue Disorders | |
| Very rare | Joint swelling |
| Very rare | Limb discomfort |
| Renal and Urinary Disorders | |
| Very rare | Renal tubular acidosis |
| Very rare | Nephrocalcinosis |
| General Disorders and Administration Site Reactions | |
| Very rare | Generalized edema |
| Very rare | Influenza like illness |
| Investigations | |
| Very rare | Weight increased |

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to:

Pusat Farmakovigilans/MESO Nasional

Direktorat Pengawasan Keamanan, Mutu dan Ekspor Impor Obat Narkotika, Psikotropika, Prekursor, dan Zat Adiktif

Badan Pengawas Obat dan Makanan Republik Indonesia

Address: Jl. Percetakan Negara No. 23, Jakarta Pusat, 10560

Email: pv-center@pom.go.id

Website: <http://e-meso.pom.go.id/>

CONTRAINDICATIONS

Hypersensitivity to any component of this product.

Migraine prophylaxis: in pregnancy and in women of childbearing potential if not using a highly effective method of contraception.

INTERACTIONS

(For purposes of this section, a no effect dose is defined as a $\leq 15\%$ change.)

Effects of other AEDs on TOPAMAX®

Phenytoin and carbamazepine decrease the plasma concentration of TOPAMAX®. The addition or withdrawal of phenytoin or carbamazepine to TOPAMAX® therapy may require an adjustment in dosage of the latter. This should be done by titrating to clinical effect. The addition or withdrawal of valproic acid does not produce clinically significant changes in plasma concentrations of TOPAMAX® and, therefore, does not warrant dosage adjustment of TOPAMAX®. The results of these interactions are summarized below:

| AED Coadministered | AED Concentration | TOPAMAX® Concentration |
|---------------------|-------------------|------------------------|
| Phenytoin | ↔** | ↓ (48%) |
| Carbamazepine (CBZ) | ↔ | ↓ (40%) |
| Valproic acid | ↔ | ↔ |
| Lamotrigine | ↔ | ↔ |
| Phenobarbital | ↔ | NS |
| Primidone | ↔ | NS |

↔ = No effect on plasma concentration ($\leq 15\%$ change)

** = Plasma concentrations increase in individual patients

↓ = Plasma concentrations decrease

NS = Not studied

AED = antiepileptic drug

Effects of TOPAMAX® on other AEDs

The addition of TOPAMAX® to other AEDs (phenytoin, carbamazepine, valproic acid, phenobarbital, primidone) has no effect on their steady-state plasma concentrations, except in the occasional patient, where the addition of TOPAMAX® to phenytoin may result in an increase of plasma concentrations of phenytoin. This is possibly due to inhibition of a specific enzyme polymorphic isoform (CYP2C19). Consequently, any patient on phenytoin showing clinical signs or symptoms of toxicity should have phenytoin levels monitored.

A pharmacokinetic interaction study of patients with epilepsy indicated the addition of topiramate to lamotrigine had no effect on steady state plasma concentration of lamotrigine at topiramate doses of 100 to 400 mg/day. In addition, there was no change in steady state plasma concentration of topiramate during or after removal of lamotrigine treatment (mean dose of 327 mg/day).

Other drug interactions

Digoxin

In a single-dose study, serum digoxin area under plasma concentration curve (AUC) decreased 12% due to concomitant administration of TOPAMAX®. The clinical relevance of this observation has not been established. When TOPAMAX® is added or withdrawn in patients on digoxin therapy, careful attention should be given to the routine monitoring of serum digoxin.

Central nervous system (CNS) depressants

Concomitant administration of TOPAMAX® and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. It is recommended that TOPAMAX® not be used concomitantly with alcohol or other CNS depressant drugs.

Contraceptives

In a pharmacokinetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), TOPAMAX® given in the absence of other medications at doses of 50 to 200 mg/day was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. In another study, exposure to EE was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when given as adjunctive therapy in patients taking valproic acid. In both studies, TOPAMAX® (50 mg/day to 800 mg/day) did not significantly affect exposure to NET. Although there was a dose-dependent decrease in EE exposure for doses between 200-800 mg/day, there was no significant dose-dependent change in EE exposure for doses of 50-200 mg/day. The clinical significance of the changes observed is not known. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX®. Patients taking estrogen-containing or progestin only contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.

Lithium

In healthy volunteers, there was an observed reduction (18% for AUC) in systemic exposure for lithium during concomitant administration with topiramate 200 mg/day. In patients with bipolar disorder, the pharmacokinetics of lithium were unaffected during treatment with topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure (26% for AUC) following topiramate doses of up to 600 mg/day. Lithium levels should be monitored when co-administered with topiramate.

Risperidone

Drug-drug interaction studies conducted under single and multiple dose conditions in healthy volunteers and patients with bipolar disorder yielded similar results. When administered concomitantly with topiramate at escalating doses of 100, 250 and 400 mg/day there was a reduction in risperidone (administered at doses ranging from 1 to 6 mg/day) systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/day doses, respectively). Minimal alterations in the pharmacokinetics of the total active moiety (risperidone plus 9-hydroxyrisperidone) and no alterations for 9-hydroxyrisperidone were observed. There were no clinically significant changes in the systemic exposure of the risperidone total active moiety or of topiramate, therefore this interaction is not likely to be of clinical significance.

Hydrochlorothiazide (HCTZ)

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of HCTZ (25 mg every 24h) and topiramate (96 mg every 12h) when administered alone and concomitantly. The results of this study indicate that topiramate C_{max} increased by 27% and AUC increased by 29% when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate dose. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination.

Metformin

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin and topiramate in plasma when metformin was given alone and when metformin and topiramate were given simultaneously. The results of this study indicated that metformin mean C_{max} and mean AUC_{0-12h} increased by 18% and 25%, respectively, while mean CL/F decreased 20% when metformin was co-administered with topiramate. Topiramate did not affect metformin t_{max} . The clinical significance of the effect of topiramate on metformin pharmacokinetics is unclear. Oral plasma clearance of topiramate appears to be reduced when administered with metformin. The extent of change in the clearance is unknown. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear. When TOPAMAX® is added or withdrawn in patients on metformin therapy, careful attention should be given to the routine monitoring for adequate control of their diabetic disease state.

Pioglitazone

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate and pioglitazone when administered alone and concomitantly. A 15% decrease in the $AUC_{\tau,ss}$ of pioglitazone with no alteration in $C_{max,ss}$ was observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in $C_{max,ss}$ and $AUC_{\tau,ss}$ respectively, of the active hydroxy-metabolite was noted as well as a 60% decrease in $C_{max,ss}$ and $AUC_{\tau,ss}$ of the active keto-metabolite. The clinical significance of these findings is not known. When TOPAMAX® is added to pioglitazone therapy or pioglitazone is added to TOPAMAX® therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.

Glyburide

A drug-drug interaction study conducted in patients with type 2 diabetes evaluated the steady-state pharmacokinetics of glyburide (5mg/day) alone and concomitantly with topiramate (150 mg/day). There was a 25% reduction in glyburide AUC_{24} during topiramate administration. Systemic exposure of the active metabolites, 4-*trans*-hydroxy-glyburide (M1) and 3-*cis*-hydroxyglyburide (M2), were also reduced by 13% and 15%, respectively. The steady-state pharmacokinetics of topiramate were unaffected by concomitant administration of glyburide. When topiramate is added to glyburide therapy or glyburide is added to topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.

Other forms of interactions:

Agents predisposing to nephrolithiasis

TOPAMAX®, when used concomitantly with other agents predisposing to nephrolithiasis, may increase the risk of nephrolithiasis. While using TOPAMAX®, agents like these should be avoided since they may create a physiological environment that increases the risk of renal stone formation.

Valproic acid

Concomitant administration of topiramate and valproic acid has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either drug alone. In most cases, symptoms and signs abated with discontinuation of either drug (see *Warnings and Precautions* and *Adverse Reactions*). This adverse reaction is not due to a pharmacokinetic interaction.

Hypothermia, defined as an unintentional drop in body core temperature to $<35^{\circ}\text{C}$, has been reported in association with concomitant use of topiramate and valproic acid (VPA) both in conjunction with hyperammonemia and in the absence of hyperammonemia. This adverse event in patients using concomitant topiramate and valproate can occur after starting topiramate treatment or after increasing the daily dose of topiramate.

Vitamin K-antagonist anticoagulant medications

Decreased Prothrombin Time/International Normalized Ratio (PT/INR) responses have been reported following concomitant administration of topiramate with vitamin K-antagonist anticoagulant medications. Closely monitor INR during concomitant administration of topiramate therapy with vitamin K-antagonist anticoagulant medications.

Additional pharmacokinetic drug interaction studies

Clinical studies have been conducted to assess the potential pharmacokinetic drug interaction between topiramate and other agents. The changes in C_{max} or AUC as a result of the interactions are summarized below. The second column (concomitant drug concentration) describes what happens to the concentration of the concomitant drug listed in the first column when topiramate is added. The third column (topiramate concentration) describes how the coadministration of a drug listed in the first column modifies the concentration of topiramate.

| Summary of Results from Additional Clinical Pharmacokinetic Drug Interaction Studies | | |
|--|--|--|
| Concomitant Drug | Concomitant Drug Concentration ^a | Topiramate Concentration ^a |
| Amitriptyline | ↔ 20% increase in C_{max} and AUC of nortriptyline metabolite | NS |
| Dihydroergotamine (Oral and Subcutaneous) | ↔ | ↔ |
| Haloperidol | ↔ 31% increase in AUC of the reduced metabolite | NS |
| Propranolol | ↔ 17% increase in C_{max} for 4-OH propranolol (TPM 50mg q12h) | 9% and 16% increase in C_{max} , 9% and 17% increase in AUC (40mg and 80mg propranolol q12h, respectively) |
| Sumatriptan (Oral and Subcutaneous) | ↔ | NS |
| Pizotifen | ↔ | ↔ |
| Diltiazem | 25% decrease in AUC of diltiazem and 18% decrease in DEA, and ↔ for DEM* | 20% increase in AUC |
| Venlafaxine | ↔ | ↔ |
| Flunarizine | 16% increase in AUC (TPM 50 mg q12h) ^b | ↔ |

^a % values are the changes in treatment mean C_{max} or AUC with respect to monotherapy

↔ = No effect on C_{max} and AUC ($\leq 15\%$ change) of the parent compound

NS = Not studied

* DEA = des acetyl diltiazem, DEM = N-demethyl diltiazem

^b Flunarizine AUC increased 14% in subjects taking flunarizine alone. Increase in exposure may be attributed to accumulation during achievement of steady state.

Pregnancy and Breast-feeding

Pregnancy

Studies in animals have shown reproductive toxicity (see *Non-Clinical Information – Reproductive and Developmental Toxicology*). In rats, topiramate crosses the placental barrier. In humans, topiramate crosses the placenta and similar concentrations have been reported in the umbilical cord and maternal blood.

There are no adequate and well-controlled studies using TOPAMAX® in pregnant women.

TOPAMAX® can cause fetal harm when administered to a pregnant woman. This has been reported with topiramate monotherapy and topiramate as part of a polytherapy regimen.

Congenital malformations

Data from pregnancy registries indicate that infants exposed to topiramate *in utero* have an increased risk of congenital malformations (e.g., craniofacial defects, such as cleft lip/palate, hypospadias, and anomalies involving various body systems).

In addition, data from these registries and other studies indicate that, compared with monotherapy, there is an increased risk of teratogenic effects associated with the use of AEDs in combination therapy. The risk has been observed in all doses and effects were reported to be dose-dependent. In women treated with topiramate who have had a child with a congenital malformation, there appears to be an increased risk of malformations in subsequent pregnancies when exposed to topiramate. There is an increased risk of pre-term labor and premature delivery associated with the use of AEDs, including topiramate.

SGA

Compared with a reference group not taking AEDs, registry data for TOPAMAX® monotherapy showed a higher prevalence of low birth weight (<2500 grams). One pregnancy registry reported an increased frequency of infants who were small for gestational age (SGA; defined as birth weight below the 10th percentile corrected for their gestational age, stratified by sex) among those exposed to topiramate monotherapy *in utero*. SGA has been observed in all doses and is dose-dependent. The prevalence of SGA is greater in women who received higher doses of topiramate during pregnancy. In addition, the prevalence of SGA for women who continued topiramate use later in pregnancy is higher compared to women who stopped its use before the third trimester. The long-term consequences of the SGA findings could not be determined. A causal relationship for low birth weight and SGA has not been established.

Neurodevelopmental disorders

- Data from an observational US cohort study did not suggest an increased cumulative incidence of autism spectrum disorder by 8 years of age in 1030 children of mothers with epilepsy exposed to topiramate *in utero*, compared with children of mothers with epilepsy not exposed to topiramate, after adjustment for indication and other confounders.
- Data from two observational population-based registry studies undertaken in largely the same dataset from the Nordic countries suggest that there may be a 2 to 3-fold higher prevalence of autism spectrum disorders, intellectual disability or attention deficit hyperactivity disorder (ADHD) in almost 300 children of mothers with epilepsy exposed to topiramate *in utero*, compared with children of mothers with epilepsy not exposed to an AED.

Epilepsy indication

It is recommended to consider alternative therapeutic options in women of childbearing potential. If TOPAMAX® is used in women of childbearing potential, it is recommended that highly effective contraception be used (see *Interactions*), and that the woman is fully informed of the known risks of uncontrolled epilepsy to the pregnancy and the potential risks of the medicinal product to the fetus. If a woman plans a pregnancy, a preconceptional visit is recommended in order to reassess the treatment, and to consider other therapeutic options. In case of administration during the first trimester, careful prenatal monitoring should be performed.

Migraine prophylaxis indication

TOPAMAX® is contraindicated in pregnancy and in women of childbearing potential if a highly effective method of contraception is not used (see *Contraindications* and *Interactions*).

Risk related to epilepsy and AEDs in general

Specialist advice should be given to women who are of childbearing potential. The need for treatment with AEDs should be reviewed when a woman is planning to become pregnant. In women being treated for epilepsy, sudden discontinuation of AED therapy should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.

TOPAMAX® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (see *Contraindications*). In treating and counseling women of childbearing potential, the prescribing physician should weigh the benefits of therapy against the risks and consider alternative therapeutic options. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Breast-feeding

Topiramate is excreted in the milk of lactating rats. The excretion of topiramate in human milk has not been evaluated in controlled studies. Limited observations in patients suggest an extensive excretion of topiramate into breast milk. Diarrhea and somnolence have been reported in breastfed infants whose mothers receive topiramate treatment. Therefore, a decision should be made whether to discontinue breast-feeding or to discontinue the drug, taking into account the benefit of breast-feeding for the child and the benefit of the drug to the mother.

In post-marketing experience, cases of hypospadias have been reported in male infants exposed in-utero to topiramate, with or without other anticonvulsants; however, a causal relationship with topiramate has not been established.

Effects on Ability to Drive and Use Machines

TOPAMAX® acts on the central nervous system and may produce drowsiness, dizziness or other related symptoms. It may also cause visual disturbances and/or blurred vision. These adverse events could potentially be dangerous in patients driving a vehicle or operating machinery, particularly until such time as the individual patient's experience with the drug is established.

Overdose

Symptoms and signs

Overdoses of topiramate have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbances, blurred vision, diplopia, mentation impaired, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after polydrug overdoses involving topiramate.

Topiramate overdose can result in severe metabolic acidosis (see *Warnings and Precautions – Metabolic acidosis and sequelae*).

The highest topiramate overdose reported was calculated to be between 96 and 110 g and resulted in coma lasting 20 to 24 hours followed by full recovery after 3 to 4 days.

Treatment

In the event of overdose, Topiramate should be discontinued and general supportive treatment given until clinical toxicity has been diminished or resolved. Hemodialysis has been shown to be an effective means of removing topiramate from the body. The patient should be well hydrated.

PHARMACEUTICAL PARTICULARS

List of Excipients

Film-coated tablets

Tablet core

Lactose monohydrate
Magnesium stearate
Microcrystalline cellulose
Pregelatinised starch
Sodium starch glycolate

Film-coating

Carnauba wax
OPADRY® white, yellow, pink, which contain the following:
Hypromellose
Polyethylene glycol
Polysorbate
Synthetic iron oxides (*yellow and pink coating only*)
Titanium dioxide

Sprinkle capsules

Sprinkle beads

Cellulose acetate
Povidone
Sugar spheres

Gelatin capsule

Gelatin
Sodium lauryl sulfate
Sorbitan monolaurate
Titanium dioxide (for the white, opaque body)

Incompatibilities

None known.

Shelf-Life

Tablets: 24 months

Sprinkle Capsule: 24 months

Special Precautions for Storage

Tablets

Store at or below 25°C and protect from moisture.
Keep out of the sight and reach of children.

Sprinkle Capsules

Store at or below 25°C and protect from moisture.
Do not store the drug/food mixture.
Keep out of the sight and reach of children.

HOW SUPPLIED

- **TOPAMAX® Tablets**

TOPAMAX® 25 mg tablet
Box 6 alu blister @ 10 tablet
Reg. No.: DKI2467100110A1

TOPAMAX® 50 mg tablet
Box 6 alu blister @ 10 tablet
Reg. No.: DKI2467100110B1

TOPAMAX® 100 mg tablet
Box 6 alu blister @ 10 tablet
Reg. No.: DKI2467100110C1

Date of First Authorisation: 8 April 1998

Manufactured by CILAG AG, Schaffhausen, Switzerland
Packaged and released by Lusomedicamenta – Sociedade Técnica Farmacêutica S.A., Barcarena, Portugal
Registered by PT Integrated Healthcare Indonesia, Jakarta – Indonesia
For adverse event and product quality complaint please contact drugsafety@jacid.inj.com or Phone (021) 2935 3935

- **TOPAMAX® Sprinkle Capsule**

TOPAMAX® Sprinkle 15 mg Capsule
Box 1 bottle @ 60 capsules
Reg. No.: DKI2210902201A1

TOPAMAX® Sprinkle 25 mg Capsule
Box 1 bottle @ 60 capsules
Reg. No.: DKI2210902201B1

Date of First Authorisation: 31 Desember 2003

Manufactured by Janssen Ortho LLC, Gurabo – Puerto Rico

Packaged and released by Janssen-Cilag S.p.A., Latina, Italy

Registered by PT. Integrated Healthcare Indonesia, Jakarta - Indonesia

For adverse event and product quality complaint please contact drugsafety@jacid.inj.com or Phone (021) 2935 3935

HARUS DENGAN RESEP DOKTER

Based on CCDS **v.27 26Jun2024**+TD BPOM 3Jun25